Catalog No.
Product Name
Application
Product Information
Citations
-
FASN inhibitor
Orlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice. Orlistat is also an inhibitor of fatty acid synthase (FASN), is used orally for long-term research of obesity. Anti-atherosclerotic effect.
- M Sugihara, .et al. , J Cell Biol, 2019, pii: jcb.201712120 PMID: 30705059
-
FASN inhibitor
Denifanstat (TVB-2640) is a Fatty Acid Synthase (FASN) inhibitor extracted from patent WO2012122391A1, compound 152, has an IC50 of 0.052 μM and an EC50 of 0.072 μM.
-
FASN Inhibitor
C 75 is an inhibitor of fatty acid synthase (FAS) reducing food intake and body weight in mice.- Vijaya Bharti, .et al. , Cell Rep, 2022, Dec 20;41(12):111826 PMID: 36543138
-
FASN inhibitor
TVB-3664 is an orally available, reversible, potent, selective and highly bioavailable fatty acid synthase (FASN) inhibitor, with IC50 values of 18 nM and 12 nM for human and mouse cell palmitate synthesis, respectively. TVB-3664 significantly reduces tubulin palmitoylation and mRNA expression. -
CB1 agonist
Leelamine hydrochloride is a tricyclic diterpene molecule that is extracted from the bark of pine trees. Leelamine hydrochloride is a cannabinoid receptor type 1 (CB1) agonist and a inhibitor of SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells that is not affected by androgen receptor status. -
FASN inhibitor
Desoxyrhaponticin is a stilbene glycoside from the Tibetan nutritional food Rheum tanguticum Maxim. Desoxyrhaponticin is a Fatty acid synthase (FAS) inhibitor, and has apoptotic effect on human cancer cells. -
hFAS inhibitor
GSK2194069 is a potent and specific inhibitor of the β-ketoacyl reductase (KR) activity of hFAS with an IC50 of 7.7 ?? 4.1 nM in an assay detecting released CoA. -
Fas receptor Antagonist
Xelafaslatide is a Fas receptor antagonist that effectively inhibits Fas receptor signaling, thereby blocking downstream apoptosis and inflammatory pathways. This compound demonstrates significant potential in suppressing neuroinflammation and microglial activation in glaucoma models, offering protection to retinal ganglion cells and preventing axonal degeneration. Xelafaslatide is relevant for research focused on glaucoma and related neurodegenerative conditions. -
Fasn/Cyp2e1/Cyp4a32 Binder
Floramanoside F is a flavonol glycoside that targets Fasn, Cyp2e1, and Cyp4a32, key enzymes associated with type 1 diabetic nephropathy. This compound exhibits a moderate free radical scavenging effect with an SC₅₀ of 25.1 μM and demonstrates weak inhibition of aldose reductase (IC₅₀ > 100 μM). By binding to these critical enzymes, Floramanoside F effectively inhibits lipid accumulation and oxidative stress, contributing to the reduction of renal inflammation and fibrosis. This reagent is valuable for research into mechanisms of type 1 diabetic nephropathy and related diabetic complications.

